CD274 and metastatic melanoma: A total of 321 metastatic melanoma patients from the MSK-IMPCAT cohort who received immunotherapies were analyzed (116 patients received a combination of anti CTLA-4 and anti PD-1/PD-L1 immunotherapies, 75 and 130 patients received anti CTLA-4 and anti PD-1/PD-L1 respectively), and the general clinicopathological characteristics of these patients are presented in Table1.